1 minute read
Achieving impact
In the 2012-2017 period of strategic funding, the Institute published over 550 articles with over 14,000 citations. Alongside our internationally recognised research, nine cutting-edge scientific facilities (bioinformatics, animal unit, flow cytometry, imaging, mass spectrometry, lipidomics, sequencing, biological chemistry and gene targeting). In addition to supporting the Institute’s research, these are made available to companies on the Babraham Research Campus and the external research community.
The Institute’s annual income in 2019 was £27.1M. Around a third of this (£9.7M) came from BBSRC as core ISP grants and non-grant income. This was matched by competitively awarded grants, and commercial use of the Institute’s facilities and services provided around £6.8M.
Advertisement
The Institute’s research, expertise and facilities aim to achieve the following outcomes: n
n
n
n
n
n
n To advance knowledge of biology in order to secure and maintain health throughout life;
To make discoveries that improve the quality of life for people around the world;
To develop innovative research technologies that advance the field and provide new insights;
To build on our foundational research by working with others to secure translation of our discoveries;
To provide excellent training for existing and future researchers, addressing the demand for skilled researchers in the bioscience sectors and respecting equality and diversity in all our activities;
To share our expertise with relevant stakeholders, including academia, industry and policymakers, to ensure that policies and healthcare practices are developed using the latest scientific findings; and
To develop a two-way relationship with the public, being open and transparent about our research by engaging people of all ages and backgrounds in order to align societal expectations with the process and outcomes of scientific research.
Achieving impact
The Institute is an active part of the Cambridge bioscience cluster, formed by the concentration of world-leading research institutes such as the University of Cambridge, Wellcome Sanger Institute and the MRC Laboratory of Molecular Biology, the Cambridge Biomedical Campus based around Addenbrooke’s Hospital, global pharma (AstraZeneca, GSK and Pfizer) and a diverse range of smaller pharmaceutical and medical biotech companies. Within Europe, the Institute is part of the EU-LIFE alliance of 15 research centres that work together to strengthen European research excellence.
